This is a routine capital injection into a subsidiary with no direct impact on SciSparc's standalone financials. Monitor NeuroThera's Nasdaq listing progress and any future dilution from the warrants, which could affect SciSparc's ownership percentage. The C$30 million valuation of SciSparc's stake is a soft number based on the placement price, not a market valuation.
Price Chart
Executive Summary
SciSparc invested C$2.7 million in its majority-owned subsidiary NeuroThera's non-brokered private placement, which raised C$5.4 million in total gross proceeds. SciSparc now holds approximately 44.6% of NeuroThera's outstanding common shares, valued at roughly C$30 million. This is a capital allocation event that increases SciSparc's exposure to its subsidiary's CNS pipeline but does not change SciSparc's own financials or provide new operational data for the parent company.
Key Financial Metrics
Key Facts
- SciSparc invested C$2.7 million in NeuroThera's non-brokered private placement, representing 50% of the C$5.4 million total gross proceeds raised.
- SciSparc subscribed for 22,500,000 units at C$0.12 per unit, each consisting of one common share and one warrant.
- Following the financing, SciSparc holds approximately 44.6% of NeuroThera's issued and outstanding common shares.
- SciSparc's stake in NeuroThera is valued at approximately C$30 million.
- NeuroThera intends to use net proceeds for general working capital and corporate expenses.
Financial Impact
SciSparc invested C$2.7 million; its stake in NeuroThera is valued at approximately C$30 million.
Risk Factors
- Warrant acceleration provision could lead to future dilution of SciSparc's ownership in NeuroThera if Nasdaq listing occurs.
- NeuroThera's clinical-stage pipeline (Tourette, Alzheimer's, autism) carries significant regulatory and development risk.
- SciSparc's market cap is only ~$4M, making the C$2.7M investment a large relative commitment that could strain liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3346796 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.29 (−0.04%) |
Oct 23, 2026 4d ago | 6-K | $1.09 | awaiting T+5 | — | $1.29 (+18.35%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.29 (+7.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.29 (+35.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 15, 2026 12d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.29 (−72.20%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.29 (+71.65%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.29 (−76.07%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.29 (−74.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers